Foreign-Trade Zone (FTZ) 35, Notification of Proposed Production Activity; PCI Pharma Services; (Pharmaceutical Products); Croydon and Philadelphia, Pennsylvania, 94704 [2024-28026]

Download as PDF 94704 Federal Register / Vol. 89, No. 230 / Friday, November 29, 2024 / Notices automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. All comments received in response to this notice, including names and addresses when provided, will be a matter of public record. Comments will be summarized and included in the package submitted to the Office of Management and Budget for reapproval of the ICR as revised. Jacqueline Emanuel, Associate Deputy Chief, National Forest System. [FR Doc. 2024–27884 Filed 11–27–24; 8:45 am] BILLING CODE 3411–15–P (section 301), depending on the country of origin. The applicable section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41). Public comment is invited from interested parties. Submissions shall be addressed to the Board’s Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is January 8, 2025. A copy of the notification will be available for public inspection in the ‘‘Online FTZ Information System’’ section of the Board’s website. For further information, contact Kolade Osho at Kolade.Osho@trade.gov. [FR Doc. 2024–28026 Filed 11–27–24; 8:45 am] Foreign-Trade Zones Board BILLING CODE 3510–DS–P B–59–2024] DEPARTMENT OF COMMERCE khammond on DSK9W7S144PROD with NOTICES Foreign-Trade Zone (FTZ) 35, Notification of Proposed Production Activity; PCI Pharma Services; (Pharmaceutical Products); Croydon and Philadelphia, Pennsylvania Foreign-Trade Zones Board [B–58–2024] PCI Pharma Services (PCI) submitted a notification of proposed production activity to the FTZ Board (the Board) for its facilities in Croydon, Pennsylvania and Philadelphia, Pennsylvania within Subzone 35L. The notification conforming to the requirements of the Board’s regulations (15 CFR 400.22) was received on November 21, 2024. Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material(s)/ component(s) and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board’s website—accessible via www.trade.gov/ ftz. The proposed finished products include: tulisokibart dosages packed in assembled device in single or multidose packaging and sotatercept dosages packed in assembled device in single or multi-dose packaging (duty-free). The proposed foreign-status materials/components include: autoinjector sub assembly for sotatercept; auto-injector sub assembly for tulisokibart; tulisokibart in pre-filled syringes; and sotatercept in pre-filled syringes (duty-free). The request indicates that certain materials/ components are subject to duties under section 301 of the Trade Act of 1974 VerDate Sep<11>2014 21:22 Nov 27, 2024 Jkt 265001 Foreign-Trade Zone (FTZ) 35, Notification of Proposed Production Activity; PCI Pharma Services; (Pharmaceutical Products); Croydon and Philadelphia, Pennsylvania PCI Pharma Services (PCI) submitted a notification of proposed production activity to the FTZ Board (the Board) for its facilities in Croydon, Pennsylvania and Philadelphia, Pennsylvania within Subzone 35L. The notification conforming to the requirements of the Board’s regulations (15 CFR 400.22) was received on November 21, 2024. Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material(s)/ component(s) and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board’s website—accessible via www.trade.gov/ ftz. The proposed finished product includes: cendakimab dosages packed in single and multi-dose packaging (dutyfree). The proposed foreign-status material/ component includes: bulk cendakimab in filled syringes (duty-free). Public comment is invited from interested parties. Submissions shall be addressed to the Board’s Executive Secretary and sent to: ftz@trade.gov. The PO 00000 Frm 00004 Fmt 4703 Sfmt 4703 Dated: November 22, 2024. Elizabeth Whiteman, Executive Secretary. [FR Doc. 2024–28024 Filed 11–27–24; 8:45 am] BILLING CODE 3510–DS–P DEPARTMENT OF COMMERCE Bureau of Industry and Security Dated: November 22, 2024. Elizabeth Whiteman, Executive Secretary. DEPARTMENT OF COMMERCE closing period for their receipt is January 8, 2025. A copy of the notification will be available for public inspection in the ‘‘Online FTZ Information System’’ section of the Board’s website. For further information, contact Kolade Osho at Kolade.Osho@trade.gov. Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Chemical Weapons Convention Provisions of the Export Administration Regulations The Department of Commerce will submit the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995, on or after the date of publication of this notice. We invite the general public and other Federal agencies to comment on proposed, and continuing information collections, which helps us assess the impact of our information collection requirements and minimize the public’s reporting burden. Public comments were previously requested via the Federal Register on August 28, 2024, during a 60-day comment period. This notice allows for an additional 30 days for public comments. Agency: Bureau of Industry and Security, Commerce. Title: Chemical Weapons Convention Provisions of the Export Administration Regulations. OMB Control Number: 0694–0117. Form Number(s): None. Type of Request: Regular submission, extension of a current information collection. Number of Respondents: 52. Average Time per Response: 33 minutes. Burden Hours: 28 hours. Needs and Uses: The Chemical Weapons Convention (CWC) is a multilateral arms control treaty that seeks to achieve an international ban on chemical weapons (CW). The CWC prohibits, the use, development, production, acquisition, stockpiling, retention, and direct or indirect transfer of chemical weapons. This collection E:\FR\FM\29NON1.SGM 29NON1

Agencies

[Federal Register Volume 89, Number 230 (Friday, November 29, 2024)]
[Notices]
[Page 94704]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-28026]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

B-59-2024]


Foreign-Trade Zone (FTZ) 35, Notification of Proposed Production 
Activity; PCI Pharma Services; (Pharmaceutical Products); Croydon and 
Philadelphia, Pennsylvania

    PCI Pharma Services (PCI) submitted a notification of proposed 
production activity to the FTZ Board (the Board) for its facilities in 
Croydon, Pennsylvania and Philadelphia, Pennsylvania within Subzone 
35L. The notification conforming to the requirements of the Board's 
regulations (15 CFR 400.22) was received on November 21, 2024.
    Pursuant to 15 CFR 400.14(b), FTZ production activity would be 
limited to the specific foreign-status material(s)/component(s) and 
specific finished product(s) described in the submitted notification 
(summarized below) and subsequently authorized by the Board. The 
benefits that may stem from conducting production activity under FTZ 
procedures are explained in the background section of the Board's 
website--accessible via www.trade.gov/ftz.
    The proposed finished products include: tulisokibart dosages packed 
in assembled device in single or multi-dose packaging and sotatercept 
dosages packed in assembled device in single or multi-dose packaging 
(duty-free).
    The proposed foreign-status materials/components include: auto-
injector sub assembly for sotatercept; auto-injector sub assembly for 
tulisokibart; tulisokibart in pre-filled syringes; and sotatercept in 
pre-filled syringes (duty-free). The request indicates that certain 
materials/components are subject to duties under section 301 of the 
Trade Act of 1974 (section 301), depending on the country of origin. 
The applicable section 301 decisions require subject merchandise to be 
admitted to FTZs in privileged foreign status (19 CFR 146.41).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
[email protected]. The closing period for their receipt is January 8, 2025.
    A copy of the notification will be available for public inspection 
in the ``Online FTZ Information System'' section of the Board's 
website.
    For further information, contact Kolade Osho at 
[email protected].

    Dated: November 22, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-28026 Filed 11-27-24; 8:45 am]
BILLING CODE 3510-DS-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.